select trial semaglutide Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months The SELECT Trial - A

When Mounjaro activates these receptors, it stimulates insulin secretion when blood glucose is elevated, suppresses glucagon release (which normally raises blood sugar), and slows gastric emptying

Take this as a sign to book your Belo day today

Clinical trials have documented modest heart rate increases averaging 2-4 beats per minute, though some patients may experience larger increases

Reach Out Today The population of patients seeking GLP-1 medications for weight loss continues to grow, and with options like sublingual semaglutide, managing weight has never been more accessible

This medication is not recommended for people with preexisting conditions, such as glaucoma, hyperthyroidism, or a history of extensive cardiovascular disease

Its also relevant for patients with specific needsthose with longstanding fatigue, low exercise tolerance, or suspected mitochondrial inefficiency shown in labs or symptoms